GITR Antibodies in Cancer: Not Ready for Prime Time

  • Clin Cancer Res. 2022 Sep 15;28(18):3905-3907. doi: 10.1158/1078-0432.CCR-22-1489.
Tatiana Hernandez-Guerrero  1 ,  Victor Moreno  1
Affiliations
  • 1. START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.
PMID: 35834593 DOI: 10.1158/1078-0432.CCR-22-1489
Abstract

Glucocorticoid-induced TNF Receptor (TNFR)-related protein (GITR) agonistic antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990.

Products